BioTheranostics announced a collaboration agreement with Celsee Diagnostics (formerly DeNovo Sciences) to investigate the technical feasibility of using BioTheranostics’ proprietary biomarkers in the development of blood-based diagnostics. These proof-of-concept studies will leverage proprietary platforms to enable molecular characterization with BioTheranostics’ biomarkers using circulating tumor cells enriched and captured with Celsee’s microfluidic platform to determine potential opportunities for further development in liquid biopsy.
BioTheranostics, 877-886-6739
Celsee Diagnostics, 734-233-3089